{"entity":{"id":"nct04817007","kind":"trial","name":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)","aka":[],"tldr":"A phase 1/2 trial of Ruxolitinib and Fedratinib in myeloproliferative neoplasms, run by Bristol-Myers Squibb, active and no longer recruiting.","summary":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) is a phase 1/2 interventional study registered as NCT04817007 by Bristol-Myers Squibb, with 216 participants enrolled, started 2021-03-22 and due to reach its primary completion in 2028-08-31. Interventions recorded: BMS-986158, Ruxolitinib and Fedratinib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04817007","url":"https://clinicaltrials.gov/study/NCT04817007"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":["ruxolitinib","fedratinib"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04817007","phase":"1/2","setting":"A Phase 1b/2 Study of BMS-986158 Monotherapy and in Combination With Either Ruxolitinib or Fedratinib in Participants With DIPSS-Intermediate or High Risk Myelofibrosis","sponsor":"Bristol-Myers Squibb","enrolled":216,"outcomes":[]},"route":"/trials/nct04817007/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"drug":[{"id":"fedratinib","kind":"drug","name":"Fedratinib","route":"/drugs/fedratinib/"},{"id":"ruxolitinib","kind":"drug","name":"Ruxolitinib","route":"/drugs/ruxolitinib/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}